^
BIOMARKER:

PD-L1 underexpression

i
Other names: PD-L1, CD274, HPD-L1, PD-L1, B7H1, PDL1, Programmed death ligand 1, B7-H1, B7-H, PDCD1L1, PDCD1LG1, PDCD1 Ligand 1, B7 homolog 1, CD274 Antigen, Programmed cell death 1 ligand 1, CD274 molecule
Entrez ID:
Related biomarkers:
Phase 3
AstraZeneca
Active, not recruiting
Last update posted :
12/03/2021
Initiation :
11/02/2015
Primary completion :
01/27/2020
Completion :
03/29/2024
PD-L1
|
PD-L1 underexpression • PD-L1 negative • PD-L1-H
|
cisplatin • carboplatin • gemcitabine • Imfinzi (durvalumab) • tremelimumab (CP-675206)
Phase 1/2
NextCure, Inc.
Recruiting
Last update posted :
08/18/2021
Initiation :
09/28/2018
Primary completion :
12/15/2023
Completion :
12/15/2023
SIGLEC15
|
PD-L1 underexpression
|
NC318
Phase 2
Fondazione IRCCS Istituto Nazionale dei Tumori,...
Active, not recruiting
Last update posted :
06/09/2021
Initiation :
05/23/2018
Primary completion :
05/31/2022
Completion :
05/31/2022
EGFR • PD-L1 • ALK • CD8 • LAG3 • HAVCR2 • TIGIT • CD33 • GZMB • ITGAM • FOXP3
|
PD-L1 expression • PD-L1 underexpression • ALK translocation • PD-1 expression • HAVCR2 expression • FOXP3 expression
|
Keytruda (pembrolizumab)
Phase 1/2
MedImmune LLC
Completed
Last update posted :
05/13/2021
Initiation :
09/05/2012
Primary completion :
02/28/2020
Completion :
02/28/2020
PD-L1
|
PD-L1 underexpression • PD-L1 negative
|
Imfinzi (durvalumab)
Phase 2
UNICANCER
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
06/16/2017
Primary completion :
01/01/2023
Completion :
12/01/2023
PD-L1 • MSI • POLE • VEGFA • CD34 • CD31 • FOXP3
|
PD-L1 underexpression • POLE mutation • FASN-L
|
Opdivo (nivolumab)
Phase 2
UNICANCER
Active, not recruiting
Last update posted :
03/10/2021
Initiation :
07/05/2017
Primary completion :
01/01/2023
Completion :
12/01/2023
PD-L1 • VEGFA • AFP • CD34 • CD31 • FOXP3
|
PD-L1 underexpression • FASN-L
|
Keytruda (pembrolizumab)
Phase 
Tatarstan Cancer Center
Recruiting
Last update posted :
04/12/2018
Initiation :
01/01/2018
Primary completion :
03/17/2019
Completion :
07/01/2019
HER-2
|
PD-L1 expression • PD-L1 overexpression • PD-L1 underexpression